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The first five cases of human tick-borne encephalitis in
Norway were reported from Tromöya, in Aust-Agder
County. Serum specimens from 317 dogs in the same geo-
graphic area were collected. An enzyme immunoassay
demonstrated antibody to human tick-borne encephalitis
virus in 52 (16.4%) of the dogs, which supports the notion
of an emerging disease.
F
irst described in humans in Austria (1), tick-borne
encephalitis (TBE) is rapidly becoming a growing
public health problem in Europe (2). Although
observations indicated antibody presence in humans in
southern Norway (3), this country has been absent from
maps visualizing TBE-endemic areas. This situation may
be changing. The first case of clinically manifest TBE in
humans in Norway was reported in 1998 (4). Four
additional cases were described from 1998 to 2001; all five
cases were from Tromøya in Aust-Agder County of
southern Norway (5). Infected dogs indicate that TBE
virus (TBEV) is present in different geographic areas. The
first case of TBE in dogs was reported by Lindblad in
Sweden (6), and later by others in Central Europe (7). We
investigated and found TBEV immunoglobulin (Ig) G in
dogs in southern Norway, an area where this virus was not
previously considered endemic. 
The Study 
From 1992 to 2000, we collected serum samples from
317 (65 breeds, 146 male, 171 female) dogs seen at a vet-
erinary clinic in Arendal, in southern Norway. The labora-
tory received 436 serum specimens. In case of multiple
specimens from one dog, collected during several months
or years, we controlled the results for possible changes in
antibody levels. 
We used two different enzyme-linked immunosorbent
assay (ELISA) techniques. The presence and level of IgG
antibodies to TBEV were tested by an enzyme immunoas-
say for the detection of IgG antibodies to TBEV
(Enzygnost Anti-TBE virus IgG, Dade Behring Marburg
GmbH, Marburg, Germany). Antibody levels >1:100 were
considered positive. Controls were obtained from the lab-
oratory InVitro (InVitro, Vienna, Austria). IgG to TBEV
was detected by a specific sheep, anti-dog, heavy and light
chain IgG antibody (A40-105P-7, Bethyl Laboratories,
Montgomery, TX) in a dilution of 1:20,000. Positive spec-
imens were confirmed by a second ELISA (Baxter-
Immuno, Orth, Austria), as previously described (7). In
this assay, titers >100 were considered to be positive.
Results
Atotal of 52 (16.4%) of 317 dogs had IgG antibodies to
TBEV; 40 (12.6%) had IgG antibody titers to TBEV >450,
while 12 dogs (3.8%) had moderate levels (>100–<450)
(Table 1). Positive serum specimens, including samples
with 11 to <100 U in the enzymeimmunoassay (EIA)-E
test, were confirmed with the Baxter-Immuno (B-I) test
(Table 2). The confirmatory test included five extra serum
samples in instances where such blood samples were
drawn; thus the number of positive specimens to be con-
firmed was 57.
We could not confirm one result (no. 287) with 116 U
in the Enzygnost (EIA-E) by the Immuno ELISA. Of the
low-positive specimens in the Enzygnost (<100 U), only
four specimens had low-positive results in the B-I ELISA;
all others were negative. Four low-positive EIA-E speci-
mens gave positive results in the B-I test. On the other
hand, 9 low-positive specimens in the EIA-E (20–37 U)
were negative by the B-I test. 
The codes were not broken until after the experiments
were performed. Thus serum specimens sampled and
coded at different times were in some cases collected from
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Table 2. Distribution of positive canine serum specimens
a  
EIA-E U  
>450 
N  EIA-E U 
>100–<450 
N  EIA-E U 
>11–<100 
N 
B-I titer    B-I titer    B-I titer   
3,200  1  3,200  0  3,200  0 
1,600  5  1,600  0  1,600  0 
800  5  800  0  800  0 
400  18  400  4  400  0 
200  12  200  2  200  1 
100  3  100  3  100  3 
Total  44    9    4 
aPositive by enzyme immunoassay E-test (EIA-E) and confirmed by a second test 
(enzyme immunoassay Baxter-Immuno [EIA-BI]). In five cases, we had two or 
more serum specimens with high positive results. All these samples were tested by 
both enzyme-linked immunosorbent assay techniques. 
Table 1. Results of serologic examination of canine serum 
specimens for antibodies to tick-borne encephalitis virus 
U  N 
<100  265 
>100  52 
Total  317 a single dog. Nevertheless, high positive antibody levels
were reproducible even after several years. In five
instances, we had two or more serum specimens from one
dog with high positive results at our disposal. All these
samples were tested by both ELISA techniques.
Only results of >450 U in the Enzygnost test could be
registered, which in two instances gave lower results in the
new specimens. The Immuno ELISA was in agreement
with the Enzygnost in case A, and it showed stable titers in
case B. In cases C and D, one could observe an increase in
titers by the B-I test. We observed seroconversion in three
cases.
The average age of the dogs at the time of blood sam-
pling was 6.6 years (0.5–15). The 52 dogs with ≥100 U
were 8.02 years versus dogs with <100 U, which were
younger, 6.29 years. The distribution of antibodies accord-
ing to the size of the dogs is shown in Table 3. A total of
34 (21.8%) of 151 large dogs had antibodies to TBEV
≥100 U versus 18 (10.8%) of 166 small and medium-sized
dogs. Large dogs were defined as having a body weight of
>20 kg. This difference is statistically significant: with
odds ratio = 2.39, χ2 = 7.03, p = 0.008 with Yates’ correc-
tion. Among dogs with >450 U, 25 (62.5%) of 40 were
large. 
Conclusions
Antibodies to TBEV were detected in 16.4% of dogs in
Aust-Agder County of southern Norway. This finding indi-
cates that TBEV is present in this geographic region.
Although the first human cases prove the existence of
TBEV in southern Norway, the levels of seropositivity in
dogs were still unanticipated in a region where TBE has
previously not been seen. 
TBE in dogs has been reported from several European
countries (7), and the number of cases is growing.
Searching for antibodies to TBEV in our canine population
would be useful since dogs are suitable serologic indica-
tors of TBEV in a geographic area, and canine serum has
been used to reveal natural epidemic foci. Our data support
the recent findings of human TBE cases in Norway and the
notion of an emerging disease, especially because the
serum samples were collected from the same geographic
area where the first human cases were described. The
changing epidemiologic situation suggests that better mon-
itoring of TBE is needed in Norway. 
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Table 3. Distribution of antibodies according to size of dog 
Breed   N positive serum specimens >100 U  N negative serum specimens <100 U  Total  % positive 
Alsatian wolf dog  7  33  40  21.2 
Bernese Mountain dog   1  7  8  14.3 
Bouvier  1  6  7  16.7 
Finnish dog  1  4  5  25.0 
Flat Coated Retriever  5  11  16  45.4 
Golden Retriever  4  21  25  19.0 
Hovawart  1  2  3  33.3 
Labrador Retriever  5  16  21  31.2 
Newfoundland dog  1  8  9  12.5 
Giant Schnauzer  3  3  6  50.0 
Rottweiler  2  7  9  28.6 
St. Bernard   3  0  3  100.0 
Total, large dogs   34  117  151  22.5 
Total, other dogs  18  148  166  10.8 
Total, all dogs  52  265  317  16.4 